Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Salvianolic Acid A Tablets in Healthy Volunteers
NCT03908242Phase 1Unknown
- Sponsor
- Peking University First Hospital
- Start
- Apr 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetes mellitus (DM) comparing Salvianolic Acid A with Placebo (2 arms). Primary endpoints: Subject incidence of treatment-emergent adverse events at 11 days, Percentage of participants with change from baseline in vital signs at 11 days and 3 more. Status: unknown.
02
Drugs
salvianolic acid a
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03908242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908242.